This Teachable Moment explores innovations that improve the ability to treat disease but increase the potential to cause harm, and thus the importance of careful consideration of who should be treated, what with, and for how long.
This review examines which patients derive benefit from being prescribed aspirin for the primary prevention of atherosclerotic cardiovascular disease.
In a nationally representative sample of older adults, this study characterizes changes in the prevalence of medication use and quantifies the frequency and types of potential major drug-drug interactions.
This Special Communication identifies and highlights articles published in 2014 that are most likely to influence medical overuse, organized into the categories of overdiagnosis, overtreatment, and methods to avoid overuse.
While direct oral anticoagulants (DOACs) hold some advantages over vitamin K antagonists, DOAC adverse effects, including bleeding, present a clinical challenge in frail older patients.
Davidson et al estimate the bleeding risk of combined anticoagulant (rivaroxaban or enoxaparin–vitamin K antagonist) and NSAID or aspirin therapy in patients with venous thromboembolism.
Reimers et al examine whether survival benefit associated with low-dose aspirin use after a diagnosis of colorectal cancer might depend on HLA class I antigen expression. Neugut provides an invited commentary.